Choosing the control arm/standard of care in clinical trials
Choosing the control arm/standard of care in clinical trials
Choosing Wisely and the National Cancer grid efforts in reducing low value cancer care in India
Building collaborations for cancer research
Defining Value in Indian healthcare: Asking the right questions
Sustainability in delivering healthcare - The Gordon McVie Lecture
Cancer survivors' stories: An African perspective
ESMO 2022: Breast and ovarian trial analysis
ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC
ESMO 2022: Highlights, commentary and analysis